CSL delays spin-off, cuts profit outlook as US vaccination rates slide
By Christine Chen and Rishav Chatterjee SYDNEY (Reuters) -Australian biotech CSL has cut its profit outlook and delayed plans to spin off its vaccine division, blaming an unprecedented fall in U.S. flu immunisation rates, which knocked its shares down as much as 16.6% to a near seven-year low. At CSL’s annual meeting in Melbourne on …
CSL delays spin-off, cuts profit outlook as US vaccination rates slide Read More »










